IPCIF Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 15:17):

Stats
Today's Volume	4 177.00
Average Volume	8 979.00
Market Cap	1.25M
EPS	$-0.0600 ( 2023-10-16 )
Next earnings date	( $0 ) 2024-06-03
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.780
ATR14	$0 (0.00%)

Intellipharmaceutics Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Intellipharmaceutics Financials

Annual	2023
Revenue:	$65 728.00
Gross Profit:	$65 728.00 (100.00 %)
EPS:	$-0.0874

Q2	2023
Revenue:	$480 203
Gross Profit:	$480 203 (100.00 %)
EPS:	$-0.00160

Q1	2023
Revenue:	$326 343
Gross Profit:	$326 343 (100.00 %)
EPS:	$-0.0107

Q4	2023
Revenue:	$29 682.00
Gross Profit:	$29 682.00 (100.00 %)
EPS:	$-0.0264

Financial Reports:

No articles found.

Intellipharmaceutics

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.